Hasil Pencarian (17430)
Halaman 209 / 349Schizophrenia is a complex mental illness and impacts approximately 1% of the population.[L10902] Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by …
Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and…
Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. Lumefantrine Co-Artemether is a tablet formulation of artemether and …
Deskripsi belum tersedia.
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulation…
Deskripsi belum tersedia.
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumili…
Deskripsi belum tersedia.
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns …
Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Lunasine is under investigation in clinical trial NCT02709330 (ALS Reversals - Lunasin Regimen).
Lunsekimig is under investigation in clinical trial NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma).
Lupeol has been investigated for the treatment of Acne.
Deskripsi belum tersedia.
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar di…
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,[A214322] and small-cell lung cancer (SCLC).[A214310] It i…
Lurtotecan is under investigation in clinical trial NCT00022594 (Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer).
Lusacomfar Alfa is a recombinant complement factor H
Luseogliflozin has been used in trials studying the treatment of Diabetes Melltius, Type 2.
Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand na…
Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferat…
Lutein is an xanthophyll and one of 600 known naturally occurring carotenoids. Lutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots. In green plants, xa…
Deskripsi belum tersedia.
A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to sp…
Lutetium Lu-177 vipivotide tetraxetan is a radioligand therapeutic agent. It consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer.[L41280] Lutetium Lu-177 vipivot…
Deskripsi belum tersedia.
Lutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).
Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein made up of monomeric units. Lutropin alfa was the first and only recombinant human form of…
Luvadaxistat is under investigation in clinical trial NCT03214588 (Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia).
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolR?) targeting antibody-drug conjugate.[A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Anti…
Luvixasertib is under investigation in clinical trial NCT05251714 (CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer).
LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vacc…
LV305 is a lentiviral vector encoding NY-ESO-1 gene. LV305 is an active component of CMB305 along with [G305].[L47346]
Deskripsi belum tersedia.
LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).
LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders. LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral se…
LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minima…
LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.
Ly2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.
LY-2183240 is an inhibitor of endocannabinoid reuptake/breakdown.[A253037]
Ly2300559 has been used in trials studying the prevention of Migraine Headache.
LY2334737 has been used in trials studying the treatment of Solid Tumor, Metastatic Tumor, and Malignant Solid Tumor.